Actively Recruiting
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
Led by Liverpool School of Tropical Medicine · Updated on 2025-06-27
2960
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
L
Liverpool School of Tropical Medicine
Lead Sponsor
K
Kenya Medical Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
There are few safe, effective, and affordable interventions to improve pregnancy outcomes in low resource settings where the highest rates of poor birth outcomes occur. L-citrulline is naturally found in many foods and is changed into another important amino acid, L-arginine, in the body. L-arginine is important for the growth of a healthy placenta and healthy baby. Adding L-citrulline to the diets of pregnant women may be an effective and affordable way to improve the health of their babies.The goal of the AGREE trial is to test whether a dietary supplement containing a common food component, an amino acid called L-citrulline, can help pregnant Kenyan women at risk of malaria have healthier pregnancies and healthier babies. 2,960 pregnant Kenyan women will be enrolled and randomly assigned to take either a twice daily dietary supplement containing L-citrulline or a placebo supplement without additional L-citrulline. Maternal participants will be seen every month until delivery and at weeks 1 and 6 after birth. Infants will also be followed up at ages 6, 12, 18, and 24 months. The primary outcome of the study is 'adverse pregnancy outcome', a composite of foetal loss (miscarriage or still birth), preterm birth, low birth weight, small for gestational age or neonatal mortality. The results of the AGREE trial could help to guide obstetric and public health policy and provide a sustainable solution that could be implemented at the community level.
CONDITIONS
Official Title
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women aged 16-40 years
- Up to 24 weeks gestation confirmed by ultrasound
- Viable singleton pregnancy
- Resident of the study area
- Willing to attend scheduled and unscheduled study visits
- Willing to deliver in a study clinic or hospital
You will not qualify if you...
- Multiple pregnancies (twins or triplets)
- Pre-existing hypertension, kidney disease, diabetes, or severe anemia (hemoglobin < 5 g/dL)
- HIV-positive or unknown HIV status
- Nonviable pregnancy or fetal malformations seen on ultrasound at enrollment
- Known allergy or contraindication to study supplements including lactose intolerance or lactose-free diet
- Unable to give consent
- Participation in another clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
KEMRI Centre for Global Health Research
Kisumu, Kenya
Actively Recruiting
Research Team
F
Feiko O. ter Kuile, PhD
CONTACT
H
Hellen C. Barsosio, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here